Comparison of chemosensitivity tests: Clonogenic assay versus MTT assay

Kazuhiko Kawada, Toshiro Yonei, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Mine Harada, Mitsune Tanimoto

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalActa Medica Okayama
Volume56
Issue number3
Publication statusPublished - 2002

Fingerprint

irinotecan
Assays
Anthraquinones
Anthracyclines
Platinum
Tumors
Neoplasms
Vinca Alkaloids
Cell Line
Etoposide
Cells
Antineoplastic Agents
Lung Neoplasms
Clinical Trials
Metabolites
Pharmaceutical Preparations

Keywords

  • 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
  • Chemosensitivity test
  • Clonogenic assay

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Kawada, K., Yonei, T., Ueoka, H., Kiura, K., Tabata, M., Takigawa, N., ... Tanimoto, M. (2002). Comparison of chemosensitivity tests: Clonogenic assay versus MTT assay. Acta Medica Okayama, 56(3), 129-134.

Comparison of chemosensitivity tests : Clonogenic assay versus MTT assay. / Kawada, Kazuhiko; Yonei, Toshiro; Ueoka, Hiroshi; Kiura, Katsuyuki; Tabata, Masahiro; Takigawa, Nagio; Harada, Mine; Tanimoto, Mitsune.

In: Acta Medica Okayama, Vol. 56, No. 3, 2002, p. 129-134.

Research output: Contribution to journalArticle

Kawada, K, Yonei, T, Ueoka, H, Kiura, K, Tabata, M, Takigawa, N, Harada, M & Tanimoto, M 2002, 'Comparison of chemosensitivity tests: Clonogenic assay versus MTT assay', Acta Medica Okayama, vol. 56, no. 3, pp. 129-134.
Kawada, Kazuhiko ; Yonei, Toshiro ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Tabata, Masahiro ; Takigawa, Nagio ; Harada, Mine ; Tanimoto, Mitsune. / Comparison of chemosensitivity tests : Clonogenic assay versus MTT assay. In: Acta Medica Okayama. 2002 ; Vol. 56, No. 3. pp. 129-134.
@article{6317b40d02b542ff9f17e7b33731012e,
title = "Comparison of chemosensitivity tests: Clonogenic assay versus MTT assay",
abstract = "When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.",
keywords = "3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Chemosensitivity test, Clonogenic assay",
author = "Kazuhiko Kawada and Toshiro Yonei and Hiroshi Ueoka and Katsuyuki Kiura and Masahiro Tabata and Nagio Takigawa and Mine Harada and Mitsune Tanimoto",
year = "2002",
language = "English",
volume = "56",
pages = "129--134",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "3",

}

TY - JOUR

T1 - Comparison of chemosensitivity tests

T2 - Clonogenic assay versus MTT assay

AU - Kawada, Kazuhiko

AU - Yonei, Toshiro

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Takigawa, Nagio

AU - Harada, Mine

AU - Tanimoto, Mitsune

PY - 2002

Y1 - 2002

N2 - When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.

AB - When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.

KW - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

KW - Chemosensitivity test

KW - Clonogenic assay

UR - http://www.scopus.com/inward/record.url?scp=0036594332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036594332&partnerID=8YFLogxK

M3 - Article

C2 - 12108583

AN - SCOPUS:0036594332

VL - 56

SP - 129

EP - 134

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 3

ER -